SABCS 2025 | Guideline-based sequencing in metastatic HER2-positive breast cancer
Azka Ali, MD, Cleveland Clinic, Cleveland, OH, comments on current guideline-based recommendations for metastatic HER2-positive breast cancer, highlighting the standard regimen of taxane chemotherapy with trastuzumab and pertuzumab. Additionally, for patients with recurrent breast cancer within 12 months, a second-line antibody-drug conjugate like trastuzumab-deruxtecan is often used. The DESTINY-Breast09 trial (NCT04784715) has shown improved outcomes with trastuzumab deruxtecan plus pertuzumab, making it a suitable option for select high-risk patients, although it is not currently approved for first-line use. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2025 Meeting in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
